文献速递骨质疏松与代谢性骨病

基线血清PINP水平与罗莫佐单抗治疗未经治疗骨质疏松女性患者髋部骨密度增加相关

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
PubMed 文献 · Osteoporos Int · 2022-12-31

这项前瞻性、观察性、多中心研究纳入63例未经治疗的绝经后骨质疏松女性,接受罗莫佐单抗治疗12个月。基线血清PINP值独立且显著与全髋和股骨颈骨密度增加≥3%相关,最佳截断值为53.7 µg/L,灵敏度54.3%、特异度92.3%。

要点

  • 基线PINP与罗莫佐单抗治疗12个月后全髋和股骨颈骨密度增加≥3%独立相关(p=0.019,95%CI 1.006-1.054)。
  • 基线PINP最佳截断值53.7 µg/L,灵敏度54.3%、特异度92.3%(AUC=0.752)。
  • 57.1%的患者在全髋或股骨颈均未达到骨密度增加≥3%,而96.8%的患者腰椎骨密度增加≥6%。

核心结论

  • 在真实世界环境中,基线PINP值与未经治疗患者接受罗莫佐单抗治疗后全髋和股骨颈骨密度增加相关。

研究设计与样本

  • 前瞻性、观察性、多中心研究,纳入63例未经治疗的绝经后骨质疏松女性,平均年龄72.6岁,接受罗莫佐单抗治疗12个月。
  • 基线腰椎T值-3.3,全髋T值-2.6,股骨颈T值-3.3,血清PINP 68.5 µg/L。

主要发现

  • 腰椎、全髋和股骨颈骨密度较基线百分比变化分别为17.5%、4.9%和4.3%。
  • 96.8%的患者腰椎骨密度增加≥6%,但57.1%的患者在全髋或股骨颈均未达到骨密度增加≥3%。
  • 多元回归分析显示仅基线PINP值与全髋和股骨颈骨密度增加≥3%显著独立相关(p=0.019,95%CI 1.006-1.054)。
  • 基线PINP最佳截断值为53.7 µg/L,灵敏度54.3%,特异度92.3%,曲线下面积0.752。

关键数值与推荐

  • 基线PINP最佳截断值53.7 µg/L,灵敏度54.3%,特异度92.3%(AUC=0.752)。
  • 骨密度增加≥3%定义为全髋和股骨颈的临床显著增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Baseline serum PINP value was significantly and independently associated with the increased bone mineral density (≥ 3%) in both total hip and femoral necks by 12 months of romosozumab treatment in patients with treatment-naive postmenopausal osteoporosis. PURPOSE: Some patients fail to obtain a sufficiently increased hip bone mineral density (BMD) by romosozumab (ROMO) treatment. This study aimed to investigate the prognostic factor for increased hip BMD with ROMO in patients with treatment-naive postmenopausal osteoporosis. METHODS: This prospective, observational, and multicenter study included patients (n = 63: mean age, 72.6 years; T-scores of the lumbar spine [LS], - 3.3; total hip [TH], - 2.6; femoral neck [FN], - 3.3; serum type I procollagen N-terminal propeptide [PINP], 68.5 µg/L) treated by ROMO for 12 months. BMD and serum bone turnover markers were evaluated at each time point. A responder analysis was performed to assess the patient percentage, and both univariate and multivariate analyses were performed to investigate the factors associated with clinically significant increased BMD (≥ 3%) in both TH and FN. RESULTS: Percentage changes of BMD from baseline in the LS, TH, and FN areas were 17.5%, 4.9%, and 4.3%, respectively. In LS, 96.8% of patients achieved ≥ 6% increased LS-BMD, although 57.1% could not achieve ≥ 3% increased BMD in either TH or FN. Multiple regression analysis revealed that only the baseline PINP value was significantly and independently associated with ≥ 3% increased BMD in both TH and FN (p = 0.019, 95% confidence interval = 1.006-1.054). The optimal cut-off PINP value was 53.7 µg/L with 54.3% sensitivity and 92.3% specificity (area under the curve = 0.752). CONCLUSIONS: In a real-world setting, baseline PINP value was associated with the increased BMD of TH and FN by ROMO treatment in treatment-naive patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kashii M, Kamatani T, Nagayama Y, et al. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int. 2022. PMID: 36585509. doi:10.1007/s00198-022-06642-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。